Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Market Closed - Toronto S.E.
Other stock markets
 03:59:50 2024-05-17 pm EDT 		5-day change 1st Jan Change
4 CAD +1.01% Intraday chart for Eupraxia Pharmaceuticals Inc. +1.27% -25.51%
May. 14 Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024 MT
May. 08 Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
MT
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board
MT
Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
AQ
Eupraxia Pharmaceuticals : Name and Address of Company - Form 6-K
PU
Top Premarket Decliners
MT
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
PR
Eupraxia Pharmaceuticals Inc.(NasdaqCM:EPRX) added to NASDAQ Composite Index
CI
Eupraxia Pharmaceuticals Inc. Brief: Begins Trading on Nasdaq Today
MT
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
PR
Eupraxia Pharmaceuticals Inc. Brief: Says to Begin Trading on Nasdaq on April 5, 2024
MT
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
PR
Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024
AQ
Eupraxia Pharmaceuticals Inc. Brief: Says incurred a net loss of US$10.6 million for Q4, versus $7.8 million for the three months ended December 31, 2022
MT
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
AQ
Eupraxia Pharmaceuticals : Name and Address of Company - Form 6-K
PU
Eupraxia Pharmaceuticals Completes Overnight Marketed Offering
MT
Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. News Eupraxia Pharmaceuticals Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW